Intech Investment Management LLC grew its stake in Harrow, Inc. (NASDAQ:HROW - Free Report) by 120.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,594 shares of the company's stock after buying an additional 12,358 shares during the period. Intech Investment Management LLC owned 0.06% of Harrow worth $758,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Swiss National Bank increased its position in shares of Harrow by 1.0% in the 4th quarter. Swiss National Bank now owns 59,300 shares of the company's stock valued at $1,990,000 after acquiring an additional 600 shares during the period. Quest Partners LLC acquired a new position in shares of Harrow in the third quarter valued at about $29,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Harrow by 10.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company's stock worth $253,000 after purchasing an additional 727 shares during the last quarter. HighTower Advisors LLC lifted its holdings in shares of Harrow by 13.8% during the fourth quarter. HighTower Advisors LLC now owns 10,127 shares of the company's stock worth $340,000 after purchasing an additional 1,227 shares during the period. Finally, Avantax Advisory Services Inc. lifted its holdings in shares of Harrow by 11.3% during the fourth quarter. Avantax Advisory Services Inc. now owns 12,534 shares of the company's stock worth $421,000 after purchasing an additional 1,273 shares during the period. Hedge funds and other institutional investors own 72.76% of the company's stock.
Analysts Set New Price Targets
HROW has been the subject of a number of recent research reports. B. Riley reduced their price target on shares of Harrow from $73.00 to $69.00 and set a "buy" rating for the company in a research report on Wednesday, December 4th. HC Wainwright reissued a "buy" rating and set a $57.00 target price on shares of Harrow in a report on Tuesday, March 18th.
Get Our Latest Analysis on Harrow
Harrow Stock Performance
NASDAQ:HROW traded up $0.22 during trading hours on Thursday, reaching $27.87. The company had a trading volume of 394,681 shares, compared to its average volume of 489,370. The firm has a market cap of $992.59 million, a PE ratio of -29.65 and a beta of 0.69. Harrow, Inc. has a 1-year low of $9.86 and a 1-year high of $59.23. The business's 50 day moving average price is $29.17 and its 200-day moving average price is $38.18. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44.
Harrow Company Profile
(
Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
See Also
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
